Homburger advised UBS Group on its issuance of USD 500 mln of 5.600 per cent. Tier 1 Capital Notes, which are redeemable at the option of UBS Group AG for the first time on December 21, 2029. The Notes are «
Tags :Homburger
Homburger appointed Allegra Arnold (pictured left) and Dilber Devitre (pictured right) to counsels. They had been both working at Homburger as senior associates. Allegra Arnold Allegra Arnold has been part of the Homburger’s team
Homburger advised UBS Group on its issuance of CHF 335 million Fixed Rate/Fixed Rate Senior Notes under its Senior Debt Programme. The Notes are governed by Swiss law and are listed on the SIX Swiss
Homburger advised UBS Switzerland as issuer and UBS Hypotheken Schweiz as guarantor on the UBS successfull completed issuance of Covered Bonds under the program in an aggregate principal amount of EUR 1.75 bn, consisting of EUR 1
Homburger advised Santhera Pharmaceuticals on its entrance into a royalty monetization financing totaling up to USD 38 m with R-Bridge, an affiliate of CBC Group, amongst Asia’s largest healthcare-focused investment firms. Santhera is monetizing 75% of
On May 30, 2024, St.Galler Kantonalbank (Sgkb) successfully issued CHF 200m 2.4% Tier 2 bonds due 2034. Zürcher Kantonalbank (Zkb) acted as sole lead manager and Sgkb as co-manager. Homburger’s team Homburger acted as counsel to Zkb
Homburger advised Lotus Bakeries on its partnership with Mondelēz International to expand and grow the Lotus Biscoff cookie brand. The partnership aims to expand and grow the Lotus Biscoff cookie brand in India and
Homburger advised Apellis Pharmaceuticals on its senior secured USD 475 million financing on all swiss legal aspects of the transaction. Homburger’s team Daniel Haeberli (pictured) led Homburger’s team which further included Laura Müller,
Homburger advised UBS on the completion (on May 13th) of its issuance of USD 1.75 bn fixed rate / fixed rate callable senior notes due to september 2030. The Notes are bail-inable (TLAC) bonds that are eligible to
Homburger advised Biopas on its sale to Swixx Biopharma, a swiss-based global commercial platform focusing on guaranteeing access to innovative medicines worldwide. The founders of Biopas will become shareholders of Swixx Biopharma. The transaction is
